Literature DB >> 6699832

Clinical associations of fibroblast growth promoting factor in scleroderma.

S R Potter, J Bienenstock, P Lee, S Wilkinson, W W Buchanan.   

Abstract

Normal adult human dermal fibroblasts were cultured in the presence of sera from 142 subjects. Results of a fibroblast proliferation assay revealed that 16 of 42 patients with scleroderma, 1 of 25 with rheumatoid arthritis, 3 of 10 with systemic lupus erythematosus, 2 of 3 with mixed connective tissue disease and 0 of 42 normal controls had values outside the normal range. The activity of fibroblast growth promoting factor (FGPF) in the scleroderma group correlated with the skin involvement but not with involvement of any other organ system. The levels of FGPF were higher in the first 2 years of disease duration than at any other time. Our data suggest that fibroblast activation may be a key process in the pathogenesis of scleroderma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6699832

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  Mitogenic activities for skin fibroblasts in the sera from untreated scleroderma patients at the early stage.

Authors:  A Igarashi; K Takehara; Y Soma; K Kikuchi; Y Ishibashi
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

2.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

3.  Increased production of an interleukin 1 (IL-1) inhibitor with fibroblast stimulating activity by mononuclear cells from patients with scleroderma.

Authors:  C I Sandborg; M A Berman; B S Andrews; G R Mirick; G J Friou
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.